DISEASE INDICATIONS: Acute Hepatic Porphyria (AHP)
MANUFACTURER: Alnylam Pharmaceuticals
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Pharmaceuticals and Medical Devices Agency (PMDA)
Givlaari, known by its generic name Givosiran, is a pharmaceutical medication used to treat a rare genetic disorder called acute hepatic porphyria (AHP). This innovative medication represents a significant advancement in the management of this condition, which is characterized by recurrent, severe attacks of abdominal pain, neurological symptoms, and potential life-threatening complications.
